The book focuses on a new interdisciplinary understanding of the metabolic syndrome (MetS) for better health maintenance. It provides an updated understanding of the underlying principles, possible targets, implementation approaches and the effectiveness of various avoidance strategies in MetS. The chapters cover a wide range of topics, including major advances in general aspects of metabolic syndrome, functional changes, new diagnostic methods, genotype-phenotype associations, the effect of exercise and multitarget pharmacotherapeutic strategies for MetS and perspectives on personalized medicine. It also discusses epigenetic mechanisms underlying MetS-related processes and epigenetic strategies to prevent related diseases. The book also presents summarized information about the associated factors and mechanisms linking cancer and MetS and to identify potential targets for the treatment of these patients. A better understanding of the various linkages will provide greater insight into the management of cancer patients by preventing MetS and related alterations. Key Features - Comprehensive information focused on the biological factors and physiological changes associated with metabolic syndrome - Updates on metabolic syndrome diagnosis and management - Summarized information on clinical implications for cancer therapy - Thoroughly referenced chapters with summaries and discussions for quick understanding The book is an informative resource for interdisciplinary scientists and researchers in life sciences and medicine. Furthermore, it, including the insulin-like growth factor (IGF-1) pathway, estrogen signaling, visceral adiposity, hyperinsulinemia, hyperglycemia, aromatase activity, adipokinase production, angiogenesis, oxidative stress, DNA damage and pro-inflammatory cytokines, and their clinical implications in cancer therapy.

Type 2 diabetes (T2D) is a complex metabolic disorder characterized by impaired glucose metabolism and pancreatic β-cell dysfunction. No effective treatments are available for T2D, although there have been many developments in the therapeutic arena. Nitric oxide (NO) is an endocrine agent with multiple and important biological roles in most mammalian tissues. NO has emerged as a central regulator of energy metabolism and body composition. NO bioavailability is decreased in T2D. Several of the pharmaceuticals used in T2D affect the NO system and perhaps even more so by the drugs we use to treat diabetic cardiovascular complications. Experimental works in animal models of T2D show promising results with interventions aimed to increase NO signaling. However, translation into human studies has so far been less successful, but more large-scale prolonged studies are clearly needed to understand its role. This book is a collection of reviews that deal with the role of nitric oxide in type 2 diabetes, providing a unique overview of NO signaling, and pointing out key areas for more detailed research. The book includes contributions about the pathophysiology of T2D, a brief history of discovery and timeline of NO research, a comprehensive overview of impaired NO metabolism in T2D, precursors of NO (i.e., L-arginine, L-citrulline, nitrate, nitrites, and NO donors), NO and T2D from genetic points of view, NO and diabetic wound healing, NO and osteoporosis, NO and hyperuricemia, NO and Alzheimer's Disease, therapeutic applications of NO and NO donors in T2D. The compilation is of great value to anyone interested in the biochemistry of NO and its relationship to diabetes.

Pharmacological and Molecular Perspectives on Diabetes is a compilation of reviews on clinical and scientific aspects of diabetes mellitus. It presents 11 contributions by eminent scholars that give the reader rational pharmacological and genetic perspectives of the disease and its treatment. The reviews approach diabetes from different angles, and highlight research that has been done to understand some questions about the molecular biology of diabetes in experimental settings. Topics of clinical significance such as the use of different hypoglycemic agents, and diabetic complications in clinical settings are also covered. Topics included in this book are: - Epigenetic alterations and type 2 diabetes mellitus - Responses to nutritional chromium supplements for type 2 diabetes mellitus - Endocrine role of osteocalcin in homeostatic regulation of glucose metabolism - Effect of diabetes on memory - Osteoarthritis in relation to type 2 diabetes mellitus: prevalence, etiology, symptoms and molecular mechanism - Infection of novel coronavirus in patients with diabetes mellitus - Role of an anti-inflammatory agent in the management of type 2 diabetes mellitus - Role of antidiabetic agents which helps regulates TCF7L2 variations in type 2 diabetes mellitus - Relationship between type 2 diabetes mellitus, PCOD and neurological disorders: role of antidiabetic drugs Comparison of different types of insulin available for type 1 diabetes treatment - Circadian rhythm disruption: special reference to type 2 diabetes mellitus - Type 2 diabetes mellitus and its complications: pharmacogenetics based correlations and circulating microRNA as biomarkers Pharmacological and Molecular Perspectives on Diabetes should prove to be of interest to all pharmaceutical and molecular biology scientists who are involved in research in anti-diabetic drug design and discovery, and practicing endocrinologists who wish to keep abreast of recent developments in the field.

Diabesity refers to the linkage of both diabetes and obesity that results in the coexistence of these 2 conditions. Research has identified pathophysiological mechanisms revolving around insulin resistance and hyperinsulinemia. Diabesity has important diagnostic and therapeutic implications. This book is a multidisciplinary review of diabesity. It highlights the various pharmacological methods of managing the condition. The book presents 10 chapters contributed by more than 40 experts from around the world. The review starts with an overview of diabesity and progressively describes the relationships of diabesity with the choice of diets and psychological factors. The chapters then cover the role of adipokines as therapeutic biomarkers before presenting research on medicinal and nutritional approaches to treat the condition. Modern approaches to diabesity treatment such as the use of new bioactive phytochemicals, mitigating meta-inflammation and laboratory techniques are also reviewed in the book. Diabesity: A Multidisciplinary Approach is a timely reference for clinicians (in endocrinology and family medicine subspecialties) and students of pharmacology and medicinal chemistry on the intricate relationship between diabetes and obesity.

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The seventh volume of this series features 6 reviews on diabetes related topics for both medical specialists and pharmacologists. - Clinical and diagnostic implications of glycated albumin in diabetes mellitus. - Development of novel therapeutic groups and bioactive compounds from herbs for diabetes management - Aspartame as a sugar substitute - Mental health, adherence, and self-management among children with diabetes - Cardioprotective effects of new generation anti-diabetic and lipid-lowering agents - Epidemiology, pathophysiology, and treatment of diabesity

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. - The failing heart in diabetes with special emphasis on prevention - Flavonoids as prominent anti-diabetic agents - Chemosensor in glucose monitoring, advances and challenges - Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives - Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications - Curcuma longa as dietary supplement and diabetes mellitus: evidence from experimental studies